A five-institution Saudi consortium spanning three cities tracked 44 Dravet syndrome patients on stiripentol combination therapy.

GCC Dravet syndrome expertise concentrates around a small number of pediatric neurology centres, not a broad national field. A 2025 multi-center study spanning five institutions, the National Neuroscience Institute at King Fahad Medical City, King Abdullah Specialist Children's Hospital, King Faisal Specialist Hospital and Research Center's Riyadh and Jeddah sites, and King Fahad Specialist Hospital in Dammam, tracked 44 SCN1A-confirmed Dravet syndrome patients on stiripentol therapy. Twenty-five patients showed a significant seizure reduction; twelve showed a mild to moderate one. That kind of coordinated, cross-city publication does not happen without an established referral and collaboration network. Our KOL Universe gate starts by mapping exactly this kind of institutional concentration before any single physician is scored.

That structure changes how AXLRx tiers influence in the GCC. A pediatric neurologist publishing as part of a five-institution national consortium carries different scientific weight than one working in isolation, and our Tier Classification gate scores that distinction directly, alongside SCN1A-genotyping capability and guideline-relevant institutional roles. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over prescribing peers.

A coordinated five-institution network doesn't mean every name in it carries equal weight.

Five questions this report answers:

Q1 - Which Saudi institutions actually generate the evidence shaping GCC Dravet syndrome treatment?

Q2 - How does AXLRx tier influence across a cross-city referral network beyond publication count?

Q3 - What verification standard clears a named KOL before it ships in the workbook?

Q4 - How many of the 44 stiripentol patients showed a significant seizure reduction?

Q5 - Which institutional capability, like SCN1A genotyping, factors into AXLRx's tiering model?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #KOLMapping #GCC #SaudiArabia #PediatricNeurology #SCN1A

Live report page:  https://axlrx.ai/dravet-syndrome/gcc/kol-mapping/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/